AIMT
Aimmune Therapeutics Inc
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 2.25B; Volume: 242.06K; AvgVol 3m: 2.10M; Beta: 1.74;
Cost estimate:
P/E: –; EPS: -4.49; EPS growth quarter/prev quarter: -5.30%;
EPS growth this year: -8.20%; EPS growth past 5 years: ;
EPS ttm: -4.49;
P/S: 3764.40; P/B: 12.47; P/Cashflow: 7.19; P/FCF: ;
Sales: 570.00K; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -92.70%; ROE – return on equity: -170.90%; LT Debt/Equity: 0.73; Total Debt/Equity: 0.73;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 0.90%; Insider Transactions:258.33%;
Institutional Ownership: 87.10%; Institutional Transactions: 2.96%;
Data update: 07.10.2020.